person · Reporting owner
snyderman nancy lynn MD
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | August 03, 2026 | August 03, 2026 |
| Axonics, Inc.AXNX · Entity 86004 | Director | November 15, 2024 | November 15, 2024 |
| Future Health ESG Corp.FHLT · Entity 83199 | Director | October 24, 2021 | October 26, 2021 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | May 14, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date August 03, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 15,395 |
Ending reported balance
After 2026-08-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-03 · Exercise / conversion · Acquired 27,948 · Balance 43,343 Row 2 · 2026-08-03 · Exercise / conversion · Acquired 16,524 · Balance 59,867 Row 3 · 2026-08-03 · Sale · Disposed 44,472 · Balance 15,395 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.07 to $50.70. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.72 · Expires 2026-09-14 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-03 · Exercise / conversion · Disposed 27,948 · Balance 0 F3: These options are fully vested in accordance with their terms. |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.72 · Expires 2026-09-14 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-03 · Exercise / conversion · Disposed 16,524 · Balance 0 F3: These options are fully vested in accordance with their terms. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy the Snyderman Trust | 20,783 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 20,783 F2: Shares are held by the Nancy Lynn Snyderman Revocable Trust (the "Snyderman Trust"), of which the reporting person is both the sole trustee and sole beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.07 to $50.70. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F2: Shares are held by the Nancy Lynn Snyderman Revocable Trust (the "Snyderman Trust"), of which the reporting person is both the sole trustee and sole beneficiary.
F3: These options are fully vested in accordance with their terms.
Axonics, Inc.
Report date November 15, 2024 · Filed November 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 1
1 source rowRow 1 · 2024-11-15 · Disposition to issuer · Disposed 14,944 · Balance 0 F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.10 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-15 · Disposition to issuer · Disposed 4,167 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.04 · Expires 2029-04-08 | Direct | 0 |
Reported balance
After 2024-11-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (The "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.
Future Health ESG Corp.
Report date October 24, 2021 · Filed October 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 11,250 |
Reported balance
After 2021-10-24 transaction · row 1
1 source rowRow 1 · 2021-10-24 · Disposition to issuer · Disposed 1,688 · Balance 11,250 F1: On October 24, 2021, the Report Person forfeited 1,688 shares to the Issuer for no consideration in connection with the expiration of the underwriters' over-allotment option. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnote | 11,262 |
Reported balance
After 2021-10-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-10-24 · Disposition to issuer · Disposed 1,689 · Balance 11,262 F2: Represents the Reporting Person's pecuniary interest in shares forfeited by Future Health ESG Associates 1, LLC to the Issuer on October 24, 2021 for no consideration in connection with the expiration of the underwriters' over-allotment option. F3: The securities are held directly by Future Health ESG Associates 1, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Future Health ESG Associates 1, LLC except to the extent of her pecuniary interest in the reported securities. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 24, 2021, the Report Person forfeited 1,688 shares to the Issuer for no consideration in connection with the expiration of the underwriters' over-allotment option.
F2: Represents the Reporting Person's pecuniary interest in shares forfeited by Future Health ESG Associates 1, LLC to the Issuer on October 24, 2021 for no consideration in connection with the expiration of the underwriters' over-allotment option.
F3: The securities are held directly by Future Health ESG Associates 1, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Future Health ESG Associates 1, LLC except to the extent of her pecuniary interest in the reported securities.
Lyra Therapeutics, Inc.
Report date May 14, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 32,000 |
Reported balance
After 2025-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-14 · Grant · Acquired 32,000 · Balance 32,000 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2022 Filed Jun 16, 2022 20:58 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 7,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-017639 · form4.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:13 UTC | Alkermes plc. ALKS · Entity 2392 | PurchaseOrdinary Shares | 427 | $23.43 | $10,004.61 |
DisclosureSEC source: 0001127602-22-008576 · form4.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,366 Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 02:26 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-030303 · form4.xml · derivative · entry 3 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 02:26 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,339 | $22.11 | $29,605.29 |
DisclosureSEC source: 0001127602-21-030303 · form4.xml · nonDerivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,939 Read SEC document |
| December 02, 2021 Filed Dec 4, 2021 02:26 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-030303 · form4.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 16:27 UTC | Future Health ESG Corp. FHLT · Entity 83199 | Disposition to issuerCommon stock, par value $0.0001 per share | 1,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-129991 · tm2131085-6_4seq1.xml · nonDerivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,262 F2 · kind: Represents the Reporting Person's pecuniary interest in shares forfeited by Future Health ESG Associates 1, LLC to the Issuer on October 24, 2021 for no consideration in connection with the expiration of the underwriters' over-allotment option. F2 · shares: Represents the Reporting Person's pecuniary interest in shares forfeited by Future Health ESG Associates 1, LLC to the Issuer on October 24, 2021 for no consideration in connection with the expiration of the underwriters' over-allotment option. F2 · price: Represents the Reporting Person's pecuniary interest in shares forfeited by Future Health ESG Associates 1, LLC to the Issuer on October 24, 2021 for no consideration in connection with the expiration of the underwriters' over-allotment option. F3 · ownership.nature: The securities are held directly by Future Health ESG Associates 1, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Future Health ESG Associates 1, LLC except to the extent of her pecuniary interest in the reported securities. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 16:27 UTC | Future Health ESG Corp. FHLT · Entity 83199 | Disposition to issuerCommon stock, par value $0.0001 per share | 1,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-129991 · tm2131085-6_4seq1.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 F1 · kind: On October 24, 2021, the Report Person forfeited 1,688 shares to the Issuer for no consideration in connection with the expiration of the underwriters' over-allotment option. F1 · price: On October 24, 2021, the Report Person forfeited 1,688 shares to the Issuer for no consideration in connection with the expiration of the underwriters' over-allotment option. Read SEC document |
| October 22, 2021 Filed Nov 2, 2021 21:16 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 2,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-006778 · primarydocument.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,844 Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:17 UTC | Future Health ESG Corp. FHLT · Entity 83199 | PurchaseWarrant · Derivative | 27,351 | $1.00 | $27,351.00 |
DisclosureSEC source: 0001104659-21-116450 · tm2127753-4_4seq1.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 27,351 Underlying: See Footnote · Not disclosed shares Expires not disclosed F1 · derivative.exercise_price: Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions. F1 · derivative.exercise_date: Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions. F1 · derivative.expiration_date: Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions. F1 · derivative.underlying: Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions. F1 · derivative.underlying_shares: Each warrant will become exercisable 30 days after the completion of the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising or reorganization transactions. F2 · ownership.nature: The securities are held directly by Future Health ESG Associates 1, LLC. The Reporting Person disclaims beneficial ownership of the securities held by Future Health ESG Associates 1, LLC except to the extent of her pecuniary interest in the reported securities. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:28 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 7,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020046 · form4.xml · derivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,585 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/14/2022. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:28 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 15,677 | $0.00 Strike: $24.72 | $0.00 |
DisclosureSEC source: 0001127602-21-020046 · form4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,677 Underlying: Ordinary Shares · 15,677 shares Expires 2031-06-14 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/14/2022. Read SEC document |
| May 26, 2021 Filed May 28, 2021 22:24 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 7,250 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-21-021187 · doc4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2031-05-25 F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:38 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,104 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-017790 · form4.xml · derivative · entry 3 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This restricted stock unit award vested in full on 5/20/2021. F1 · derivative.expiration_date: This restricted stock unit award vested in full on 5/20/2021. Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:38 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,404 | $21.92 | $30,775.68 |
DisclosureSEC source: 0001127602-21-017790 · form4.xml · nonDerivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:38 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-017790 · form4.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:05 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 1,025 | $9.72 | $9,963.00 |
DisclosureSEC source: 0000899243-20-034285 · doc4.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025 Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 21:35 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,578 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030579 · form4.xml · derivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,578 Underlying: Ordinary Shares · 5,578 shares Expires not disclosed F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 12/2/2021. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 21:35 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,509 | $0.00 Strike: $18.82 | $0.00 |
DisclosureSEC source: 0001127602-20-030579 · form4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,509 Underlying: Ordinary Shares · 11,509 shares Expires 2030-12-02 F1 · derivative.exercise_date: This option becomes exercisable in full on 12/2/2021. Read SEC document |
| October 27, 2020 Filed Oct 30, 2020 00:45 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 14,500 | $0.00 Strike: $11.76 | $0.00 |
DisclosureSEC source: 0000899243-20-029782 · doc4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2030-10-26 F1 · derivative.exercise_date: This option vests and becomes exercisable in 36 monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following October 27, 2020. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 20:18 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-005682 · primarydocument.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,583 Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:24 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 6,104 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-017776 · form4.xml · derivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/20/2021. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:24 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 12,823 | $0.00 Strike: $16.85 | $0.00 |
DisclosureSEC source: 0001127602-20-017776 · form4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,823 Underlying: Ordinary Shares · 12,823 shares Expires 2030-05-20 F1 · shares: This option and restricted stock unit award together represent 50% of the approved value of the non-employee director annual equity grant. The remaining portion of such grant has been delayed, and is subject to downward adjustment, due to the uncertainty posed by the COVID-19 pandemic. F2 · derivative.exercise_date: This option becomes exercisable in full on 5/20/2021. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 18:59 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantStock Option (Right to Buy) · Derivative | 4,167 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001562180-19-004492 · primarydocument.xml · derivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 4,167 shares Expires 2029-08-22 F1 · derivative.exercise_date: The shares subject to the option will vest in full on August 18, 2020. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 18:59 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004492 · primarydocument.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,083 Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 18:51 UTC | Axonics, Inc. AXNX · Entity 86004 | PurchaseCommon Stock | 2,000 | $37.12 | $74,240.00 |
DisclosureSEC source: 0001562180-19-003721 · primarydocument.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| May 22, 2019 Filed May 23, 2019 22:38 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 22,400 | $0.00 Strike: $25.04 | $0.00 |
DisclosureSEC source: 0001127602-19-019717 · form4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,400 Underlying: Ordinary Shares · 22,400 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/22/2020. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 21:20 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.04 | $0.00 |
DisclosureSEC source: 0000899243-19-010424 · doc4.xml · derivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-04-08 F1 · derivative.exercise_date: The option becomes exercisable in full on April 8, 2020, provided the reporting person remains in continuous service through such date. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 21:20 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-010424 · doc4.xml · nonDerivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 23, 2018 Filed May 24, 2018 22:27 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $45.64 | $0.00 |
DisclosureSEC source: 0001127602-18-018855 · form4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2028-05-23 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/23/19. Read SEC document |
| May 24, 2017 Filed May 25, 2017 22:05 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 14,200 | $0.00 Strike: $58.25 | $0.00 |
DisclosureSEC source: 0001127602-17-019450 · form4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 Underlying: Ordinary Shares · 14,200 shares Expires 2027-05-24 F1 · derivative.exercise_date: This option becomes exercisable in full on 5/24/18. Read SEC document |
| September 14, 2016 Filed Sep 15, 2016 21:03 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 16,200 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001127602-16-062563 · form4.xml · derivative · entry 2 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,200 Underlying: Ordinary Shares · 16,200 shares Expires 2026-09-14 F2 · derivative.exercise_date: This option becomes exercisable in full on 9/14/17. Read SEC document |
| September 14, 2016 Filed Sep 15, 2016 21:03 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 27,400 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001127602-16-062563 · form4.xml · derivative · entry 1 snyderman nancy lynn MD · CIK 0001675198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Underlying: Ordinary Shares · 27,400 shares Expires 2026-09-14 F1 · derivative.exercise_date: This option vests in 3 equal annual installments commencing on 9/14/17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.